0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Calcium Dependence of Somatostatin (SRIF) Release and Cyclic AMP Levels in Cultured Diencephalic Neurons

      , ,

      Neuroendocrinology

      S. Karger AG

      Somatostatin, Cyclic AMP, Calcium, Neurons, Calmodulin

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Calmodulin has been reported to be involved in the Ca<sup>2+</sup>-dependent hypothalamus in vitro. The present experiments were undertaken to determine whether at an early stage of development (in diencephalic primary cultures secreting SRIF, on the 11<sup>th</sup> day) the activation of a Ca<sup>2+-</sup>calmodulin kinase system is also involved in the release of the peptide. Since a calmodulin-dependent adenylate cyclase activity has been detected in the brain, we measured intracellular cyclic AMP accumulation as an additional parameter of calmodulin activity. SRIF release and cyclic AMP accumulation were stimulated by K<sup>+</sup> (56 m M) and by the Ca<sup>2+</sup> ionophores ionomycin (0.5 µ M) and A 23187 (in a dose-dependent manner). Incubation of cells in Ca<sup>2+</sup>-free Locke medium or in the presence of Co<sup>2+</sup> (1 m M) completely blocked ionophore-induced SRIF release and cyclic AMP accumulation. Three calmodulin antagonists (calmidazolium, W-7, and chlorpromazine) and two blockers of calmodulin-dependent kinase (phenytoin and diazepam) were tested on evoked-SRIF release and cyclic AMP formation. Neither W-7 nor calmidazolium modified A 23187-induced SRIF release at any dose tested, although they inhibited, in a dose-dependent manner, the stimulatory effect of the Ca<sup>2+</sup> ionophore on cyclic AMP accumulation. High concentrations of chlorpromazine (100 µ M) were needed to decrease A 23187-induced SRIF release by 45% whereas the same concentration completely blocked the cyclic AMP accumulation evoked by the ionophore (1 µ M). K<sup>+</sup>-induced SRIF release was not modified by 0.5 µ M calmidazolium but was inhibited by rather high concentrations of W-7 (100 µ M); both antagonists significantly decreased K<sup>+</sup>-evoked cyclic AMP accumulation. Phenytoin (1 µ M to 100 µ M) and diazepam (20 µ M) failed to block the stimulatory effect of A 23187 (0.5 µ M) on either parameter. The present results: (1) confirm the Ca<sup>2+</sup>-dependence of SRIF release in fetal diencephalic cells but without the participation of calmodulin-dependent mechanisms; (2) show that agents which increase cytosolic calcium also stimulate cyclic AMP formation, probably by stimulating a calmodulin-dependent adenylate cyclase, and (3) suggest that a relationship between these two events is unlikely in the model used here.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1989
          1989
          02 April 2008
          : 49
          : 5
          : 555-560
          Affiliations
          Laboratoire de Neurobiologie Endocrinologique, UA 1197 CNRS, Université de Montpellier 2, France
          Article
          125167 Neuroendocrinology 1989;49:555–560
          10.1159/000125167
          2566943
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Original Paper

          Comments

          Comment on this article